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Abstract
Background: About 40% of all patients with genital prolapse report stress-incontinence. In about half of the 60% 
patients that do not report stress-incontinence, occult urinary stress-incontinence can be detected. In these patients 
stress-incontinence is masked due to kinking or compression of the urethra by the prolapse.
In case surgical correction is indicated there are two strategies to manage patients with combined prolapse and
(occult) stress incontinence. This strategy is either (i) a combination of prolapse surgery and stress-incontinence
surgery or (ii) to correct the prolapse first and evaluate afterwards whether additional stress-incontinence surgery is
indicated. The advantage of combining prolapse and stress-incontinence surgery is that only few patients report
stress-incontinence following such combination. However, this combination has been associated with an increased
risk on complications, of which the development of obstructive micturition symptoms, overactive bladder symptoms
and bladder retention are the most important ones. Furthermore, combining two procedures may be unnecessary as
performing only prolapse surgery may cure stress-incontinence
In the randomized CUPIDO trials both strategies are compared in patients with prolapse and evident stress
incontinence (CUPIDO I trial) and in patients with prolapse and occult stress incontinence (CUPIDO II trial).
Methods/Design: The CUPIDO trials are two multicenter randomized controlled trials in which women with stress 
urinary incontinence (SUI) or occult stress urinary incontinence (OSUI) are randomized to prolapse surgery combined 
with anti incontinence surgery (concomitant surgery) or to prolapse surgery only. Patients with at least stage 2 POP are 
eligible, women with evident SUI are randomized in CUPIDO I. Patients without SUI are eligible for CUPIDO II and will 
have urodynamic evaluation or a standardized redression test. Women with OSUI are randomized, women without 
OSUI are followed up but not randomized.
The primary outcome measure is absence of SUI twelve months after surgery. Furthermore, economic evaluations are
conducted, and the effectiveness of urodynamic investigation is evaluated against a non-invasive way to determine
SUI in women with POP.
A total of 450 women will be included in the study.
Trial Registration: Trial registration http://www.trialregister.nl NTRR 1197 en 1070van der Steen et al. BMC Women's Health 2010, 10:16
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Background
About 40% of the women with pelvic organ prolapse
(POP) also report stress urinary incontinence (SUI) [1]. If
a woman with an indication for POP surgery does not
report stress incontinence before surgery, the risk on de
novo stress incontinence is reported to be 11-20% [2,3].
In the patients who leak during a pre-operative stress test
during redression of the prolapse (defined as occult stress
incontinence, OSUI) the risk on de novo stress inconti-
nence may even be as high as 80% [4,5]. The underlying
mechanism of occult stress incontinence is that the pro-
lapse prevents stress incontinence by kinking or com-
pression of the urethra. After the prolapse is surgically
corrected the prolapse does not mask stress incontinence
anymore.
In case of abdominal POP surgery, the CARE trial has
shown that combining abdominal sacrocolpopexy with
Burch colposuspension may decrease the risk of postop-
erative urinary incontinence without increasing other
lower urinary tract symptoms [6]. Similar RCT's in
patients undergoing vaginal POP surgery have not yet
b e e n  p u b l i s h e d .  A s  a  c o n s e q u e n c e ,  i t  i s  s t i l l  d e b a t a b l e
whether vaginal POP surgery should be combined with a
midurethral sling procedure or not.
Combining vaginal prolapse repair with anti-inconti-
nence surgery showed to be an effective treatment for
SUI in observational studies [7-10], but literature about
possible side effects like obstructive voiding symptoms,
overactive bladder symptoms or bladder retention is not
consistent [8,10-15]. Concomitant surgery could lead to a
higher success rate in curing SUI, but could also lead to
overtreatment with the possible side effects of a midure-
thral sling procedure.
A randomized controlled trial published by Borstad et
al showed that in case of co-existing complaints (evident
SUI) prolapse repair gave a 3 months success rate in cur-
ing SUI of 29%. About 70% of patients still had SUI after
surgery, but in part of these women the complaints were
so minimal, that they declined the TVT procedure 3
months after the prolapse surgery [16].
In patients without evident SUI it is unclear how to pre-
dict the risk of postoperative SUI and how high this risk
is. Possibly, this could be predicted using a stress test with
redression of the prolapse during clinical examination or
urodynamic investigation [17-19]. The patients that have
a positive redression test (OSUI) may be at highest risk of
developing postoperative SUI, and might benefit from
combining prolapse surgery with a midurethral sling pro-
cedure.
We designed two randomized controlled trials to evalu-
ate the clinical value of combining prolapse surgery and
stress incontinence surgery. The trials are referred to as
CUPIDO which means: Concomitant surgery and Urody-
namic investigation in genital Prolapse and stress Inconti-
nence. A Diagnostic study including Outcome evaluation.
CUPIDO I is a trial that evaluates whether concomitant
surgery leads to better results in patients with evident
SUI than prolapse repair only.
CUPIDO II is a trial that evaluates concomitant surgery
versus prolapse surgery only in patients with OSUI.
Methods/Design
CUPIDO I Study aims
The primary aim of the CUPIDO I study is to determine
whether combined prolapse surgery and anti-inconti-
nence surgery in patients with POP and SUI results in less
SUI postoperatively than correcting only the prolapse.
Secondary aim is to find out whether concomitant sur-
gery leads to an increase of adverse events, like obstruc-
tive voiding symptoms and detrusor overactivity.
Design
The CUPIDO I trial is a multicenter randomized con-
trolled trial. All patients with POP and SUI will be ran-
domized for concomitant surgery or prolapse surgery
only. SUI is defined as a history of SUI at least once a
week and/or a positive cough test on examination, with-
out redression of the prolapse.
Determination and identification of eligible patients
Eligible patients will be selected by gynaecologists of all
participating hospitals in the Netherlands (Table 1). All
women with at least stage 2 POP in whom operative cor-
rection of the prolapse is considered, will be asked for
informed consent to participate in the trial (Figure 1).
Women will be excluded in case of previous incontinence
surgery, recent or current pregnancy, wish for pregnancy
in the future, history of bladder- or urethrasurgery, sys-
temic disease which can affect the bladder function,
chemo- or radiotherapy for cancer, chronic retention of
the bladder (> 300 ml), rectocele only, and participation
in another intervention study which can have influence
on the findings in this trial (Table 2).
Interventions
Patients are randomized for either combination surgery
or for prolapse surgery only. Combination surgery is
defined as a combination of prolapse surgery and stress
incontinence surgery. Prolapse surgery can be a vaginal
hysterectomy or sacrospinous fixation, Manchester
Fothergill operation, anterior colporrhaphy or mesh
implantation, posterior colporrhaphy or mesh implanta-
tion and enterocele repair. Anti-incontinence surgery can
be a midurethral sling, either using the retropubic route
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or the trans-obturator route. Types of surgery that are not
allowed in the study are abdominal prolapse surgery, con-
ventional techniques like a Kelly plication, colpocleisis
and the use of mini-slings.
Randomization
Patients with SUI will be randomized through a website
according to a computer-generated randomization
sequence. The randomization sequence is computer gen-
erated with a block size of four. Stratified randomization
is applied for centre and leading edge of the prolapse.
Randomization will be 1:1 for concomitant surgery and
prolapse surgery only. The data are web based registered.
Women receive a case number at randomization to treat
their data anonymously.
CUPIDO II Study aims
The primary aim of the CUPIDO II study is to compare
postoperative SUI in combined prolapse and anti-incon-
tinence surgery or prolapse surgery only in patients with
OSUI. Secondary aim is to determine whether concomi-
tant surgery leads to more adverse events, like obstruc-
tive voiding symptoms and detrusor overactivity.
Furthermore we want to evaluate the clinical value of a
standardized redression test (on clinical examination or
urodynamic investigation) to predict postoperative SUI.
This could help to select patients that could benefit from
concomitant surgery.
Study design and setting
The CUPIDO II trial is a multicenter randomized con-
trolled trial with a diagnostic cohort study. Women are
enrolled with POP and no history of SUI and a negative
cough test on examination. If OSUI is determined on
clinical examination or urodynamic investigation, using a
cough test while redressing the prolapse, these women
are also randomized for concomitant surgery or prolapse
surgery alone (CUPIDO II - randomisation). If no occult
SUI is found, the risk of developing postoperative SUI is
considered low. These women are not randomized and
only prolapse surgery is performed (CUPIDO II - follow
up). The follow up for these patients is similar to the
Figure 1 Flowchart CUPIDO I.van der Steen et al. BMC Women's Health 2010, 10:16
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women who were randomized in CUPIDO II, and is used
to determine the need for urodynamic investigation in
these patients, and the value of a standardized redression
test. The outline of the CUPIDO II trial is shown in Fig-
ure 2.
Determination and identification of eligible patients
Eligible patients will be selected by gynaecologists of all
participating hospitals in the Netherlands (Table 1). All
women with at least stage 2 POP in whom operative cor-
rection of the prolapse is considered will be asked for
informed consent to participate the trial. Patients without
SUI will have a stress test with redression of the prolapse,
either on clinical examination or during urodynamic
investigation. Patients with predominant urge inconti-
nence are excluded. Women will also be excluded in case
of previous incontinence surgery, recent or current preg-
nancy, wish for pregnancy in the future, history of blad-
der- or urethrasurgery, systemic disease which can affect
the bladderfunction, chemo- or radiotherapy for cancer,
chronic retention of the bladder (> 300 ml), and partici-
pation in another intervention study which can have
influence on the findings in this trial (Table 3).
Interventions
Patients are randomized for concomitant surgery or pro-
lapse surgery only. Prolapse surgery can be a vaginal hys-
terectomy or sacrospinous fixation, Manchester
Fothergill operation, anterior colporrhaphy or mesh
implantation, posterior colporrhaphy or mesh implanta-
tion and enterocele repair. Anti-incontinence surgery can
be a midurethral sling, either using the retropubic route
or the trans-obturator route. Types of surgery that are not
allowed in the study are abdominal prolapse surgery, con-
ventional techniques like a Kelly plication, colpocleisis
and the use of mini-slings.
Randomization
Patients with OSUI can be randomized after the redres-
sion test. The randomization sequence is computer gen-
erated with a block size of four. Stratified randomization
is applied for centre and leading edge of the prolapse.
Randomization will be 1:1 for concomitant surgery and
prolapse surgery only. The data are web based registered.
Women receive a case number at randomization to treat
their data anonymously.
Outcome measurements
The outcome measures are equal for both trials. Their
primary outcome is absence of urinary (stress) inconti-
nence and subsequent treatment for urinary (stress)
incontinence 12 months after surgery. Secondary out-
comes are absence of SUI at 6 months after surgery, ana-
tomical results and repeated treatment for pelvic organ
prolapse, disease specific and general quality of life, mor-
bidity and quality of life, and quality adjusted life-years at
6 and 12 months postoperatively. We will also study gen-
eral satisfaction and costs.
Patients in the studies will be followed from surgery
until 12 months later. Follow up will consist of various
elements. At inclusion the following data will be
recorded:
1. History and clinical examination
2. 48 hour voiding diary
3. Dutch validated version of the Urinary Distress
Inventory, a disease specific questionnaire comprising 17
questions, to assess the presence and experienced dis-
Table 1: Participating hospitals in the Netherlands.
Academic Medical Center, Amsterdam
Alant Vrouw, Bilthoven
Deventer Hospital, Deventer
Martini Hospital, Groningen
Maxima Medical Center, Eindhoven
Medical Center Leeuwarden, Leeuwarden
Reinier de Graaf Groep, Delft
Sint Antonius Hospital, Nieuwegein
TweeSteden Hospital, Tilburg
Twenteborg Hospital, Almelo
University Medical Center, Groningen
University Medical Center, Nijmegen
University Medical Center, Maastricht
VieCuri Medical Center, Venlo
Table 2: Inclusion and exclusion criteria CUPIDO I.
Inclusion criteria Exclusion criteria
≥ 18 years old Inability to give informed consent
≥ stage 2 prolapse (Recent or planned) pregnancy
Intended surgery for 
prolapse
Previous anti-incontinence surgery
Recent prolapse surgery (<6 
months)
Previous surgery to bladder or 
urethra or diverticulum
Systemic disease which could 
influence bladder function
Planned chemo- or radiotherapy for 
neoplasm
Participation in another study which 
could influence the results
Chronic urinary retention
Not predominant SUI (urge 
incontinence)
Rectocele only
Table 1: Participating hospitals in the Netherlands.
Academic Medical Center, Amsterdam
Alant Vrouw, Bilthoven
Deventer Hospital, Deventer
Martini Hospital, Groningen
Maxima Medical Center, Eindhoven
Medical Center Leeuwarden, Leeuwarden
Reinier de Graaf Groep, Delft
Sint Antonius Hospital, Nieuwegein
TweeSteden Hospital, Tilburg
Twenteborg Hospital, Almelo
University Medical Center, Groningen
University Medical Center, Nijmegen
University Medical Center, Maastricht
VieCuri Medical Center, Venlovan der Steen et al. BMC Women's Health 2010, 10:16
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comfort of pelvic floor problems. The UDI consists of 5
domains: discomfort/pain, urinary incontinence, overac-
tive bladder, genital prolapse, and obstructive micturi-
tion. The total UDI score is defined as the average of the 5
domain scores, and can be used to assess cost effective-
ness by measuring quality of life [20,21].
4. Short Form 36, with 36 questions on physical, mental
and social health to assess generic quality of life [22].
5. EQ-5D, a disease non-specific quality of life ques-
tionnaire, to derive health utilities and the corresponding
quality adjusted life years (QALYs) This is the change in
quality of life induced by the treatment multiplied by the
duration of treatment effect [23,24].
6. Health and Labour Questionnaire Short Form, to
measure the impact of disease and treatment on absence
from work, reduced productivity, unpaid labor produc-
tion, and labor- related problems [25]
7. GIS question, a global impression of the prolapse and
urinary complaints
8. Stress test with a bladder volume of at least 300 mil-
lilitres. The patient is instructed to cough four or five
times while lying in lithotomy position. In case of a nega-
tive stress test, the test is repeated with redression of the
prolapse. This is done by repositioning the cervix or vagi-
nal vault using a cotton swab.
9. Post-voiding residual bladder volume measured by
ultrasound
10. Examination of the prolapse using POP-Q
11. Examination of pelvic floor function
Follow up visits are planned with the patient's attending
gynaecologist 6 weeks, 6 months and 12 months after
surgery and exist of clinical examination including POP-
Q, subjective full bladder stress test, residual bladder vol-
ume and detection of complications such as erosions.
Along with the visits to the gynaecologist patients will
receive the questionnaires and voiding diaries.
Ethical considerations
Both studies have been approved by the Medical Ethical
Committee of the Academic Medical Centre Amsterdam,
December 2007. Full ethical approval for these studies
has been obtained. (CMO number 07.17.1758). All par-
Figure 2 Flowchart CUPIDO II.van der Steen et al. BMC Women's Health 2010, 10:16
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ticipating centres obtained approval of their local Medi-
cal Ethical Committees.
Economic evaluation
Cost effectiveness is evaluated using the costs per patient
without of SUI at 12 months after surgery as the primary
outcome measure. In addition, the cost utility is evaluated
using the costs per quality adjusted life-year as the pri-
mary outcome measure. We aim to evaluate, from a soci-
etal perspective, whether concomitant surgery is more
cost effective than prolapse surgery alone, with inconti-
nence surgery in second stage if needed. We also want to
evaluate whether the use of urodynamic investigation in
continent women prior to surgery is more cost effective
than non invasive methods to screen for OSUI. Incre-
mental cost-effectiveness analyses will be performed and
corresponding cost-effectiveness acceptability curves will
be drawn for different values of society's willingness to
pay to prevent one extra patient without SUI or to gain an
extra quality adjusted life-year. Costs include direct med-
ical costs, non-direct medical costs, and indirect costs of
lost days at work and lost productivity while at work.
The needed data on resource use and health status will
be gathered prospectively in case record forms and with
patient questionnaires, in particularly, the Health and
Labour Questionnaire short form and the EQ-5D.
Unit costs will be based on the Dutch 2004 guidelines
for costing in health care research and indexed for base
year 2008 using yearly general consumer price indi-
ces[26].
Quality adjusted life years will be derived from the
observed EQ-5D health score profiles at baseline and
during follow up by using available time trade-off based
health valuation algorithms (and assuming each score
profile to represent a patient's health status in-between
the actual and the previous measurement [23,24].
Sample size calculation
CUPIDO I trial
Of women with POP and predominant SUI 70% are
expected to be cured of their SUI by prolapse surgery. A
20% increase in success rate is expected in concomitant
surgery. For each arm 57 women are needed to prove the
hypothesis with a power of 80% and one sided testing at
0.05. Taking into account 10% loss to follow up a total of
126 patients will be included in the study. We expect that
30% of the patients with POP will meet the criteria for the
study.
CUPIDO II trial
For the group of women with occult SUI 73 are needed in
each arm to prove a 15% difference in SUI 12 months
postoperatively in concomitant surgery and prolapse sur-
gery without midurethral sling (95% versus 80% conti-
nence respectively), with a power of 80% and α of 0.05.
Taking into account 10% loss to follow up 160 patients
will be randomized. We expect 60% of the patients with
POP to meet the criteria for the study, and 50% of these
patients to have OSUI. We will therefore include 320
women in the study to perform urodynamic investiga-
tion.
Statistics
The analysis is performed according to the intention to
treat principle. Data will be presented as numbers (per-
centage) for nominal variables or means (standard devia-
tion) for interval variables. For interval variables,
differences between the two groups will be analyzed with
a Students t-test, proportions will be compared using the
Chi-square test.
Time plan
Inclusion for the Cupido study began in November 2007.
The inclusion is planned to be finished in July 2010 for
Cupido 1 and in March 2011 for Cupido 2. Patients are
followed up to 12 months after surgery, so this will take
until July 2011 and March 2012 for Cupido 1 and 2
respectively. The study is conducted in several Dutch
centers assembled in the urogynaecology consortium.
This consortium consists of Dutch centers cooperating in
multicenter trials.
Knowledge transfer
T o date it is unknown whether prolapse surgery should
be combined with a midurethral sling in patients with
SUI or OSUI. These studies will provide an answer to the
question if concomitant surgery is preferred above single
prolapse surgery in women with SUI and OSUI. This
Table 3: Inclusion and exclusion criteria for CUPIDO II.
Inclusion criteria Exclusion criteria
≥ 18 years old Inability to give informed consent
≥ stage 2 prolapse (Recent or planned) pregnancy
Intended surgery for 
prolapse
Previous anti-incontinence 
surgery
Recent prolapse surgery (<6 
months)
Previous surgery to bladder or 
urethra or diverticulum
Systemic disease which could 
influence bladder function
Planned chemo- or radiotherapy 
for neoplasm
Participation in another study 
which could influence the results
Chronic urinary retention
Cupido 2: SUI ≥ once a week OR 
positive cough testvan der Steen et al. BMC Women's Health 2010, 10:16
http://www.biomedcentral.com/1472-6874/10/16
Page 7 of 7
study will be the starting point for a doctor's thesis. The
outcomes of the study will be shared in different national
and international scientific societies, and hopefully the
results will be published in international scientific jour-
nals.
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